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Abstract
Background: Intermittent preventive treatment of malaria in children (IPTc) is a promising strategy for malaria control. A
study conducted in Mali in 2008 showed that administration of three courses of IPTc with sulphadoxine-pyrimethamine (SP)
and amodiaquine (AQ) at monthly intervals reduced clinical malaria, severe malaria and malaria infection by .80% in
children under 5 years of age. Here we report the results of a follow-on study undertaken to establish whether children who
had received IPTc would be at increased risk of malaria during the subsequent malaria transmission season.
Methods: Morbidity from malaria and the prevalence of malaria parasitaemia and anaemia were measured in children who
had previously received IPTc with SP and AQ using similar surveillance methods to those employed during the previous
intervention period.
Results: 1396 of 1508 children (93%) who had previously received IPTc and 1406 of 1508 children (93%) who had previously
received placebos were followed up during the high malaria transmission season of the year following the intervention.
Incidence rates of clinical malaria during the post-intervention transmission season (July –November 2009) were 1.87 (95%
CI 1.76 –1.99) and 1.73 (95% CI; 1.62–1.85) episodes per child year in the previous intervention and placebo groups
respectively; incidence rate ratio (IRR) 1.09 (95% CI 0.99 –1.21) (P = 0.08). The prevalence of malaria infection was similar in
the two groups, 7.4% versus 7.5%, prevalence ratio (PR) of 0.99 (95% CI 0.73–1.33) (P = 0.95). At the end of post-intervention
malaria transmission season, the prevalence of anaemia, defined as a haemoglobin concentration,11g/dL, was similar in
the two groups (56.2% versus 55.6%; PR = 1.01 [95% CI 0.91 – 1.12]) (P = 0.84).
Conclusion: IPTc with SP+AQ was not associated with an increase in incidence of malaria episodes, prevalence of malaria
infection or anaemia in the subsequent malaria transmission season.
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Introduction
Malaria is one of the most important infectious diseases in the
world and 40% of the world’s population is at risk. Despite
increasing use of current control strategies such as rapid diagnosis
and treatment of clinical cases, use of insecticide impregnated
materials and indoor residual spraying with insecticides, malaria
remains an important cause of morbidity and mortality,
particularly in sub-Saharan Africa. More than 90% of the deaths
due to malaria occur in this region and 88% of these deaths occur
in children aged less than 5 years of age [1].
Intermittent preventive treatment of malaria (IPT), defined as
the administration of a curative dose of an anti-malarial drug or
drug combination at predefined time intervals to an at risk
population regardless of whether or not they are known to be
infected, is a promising new strategy for malaria control in areas
where the infection still causes substantial morbidity and mortality
[2]. Given to infants through the Expanded Programme of
Immunization (EPI), IPT reduced the incidence of clinical malaria
by 30% [3]. More marked reductions in the incidence of
uncomplicated and severe malaria, in the range of 67% to 86%,
have been obtained when children aged 0–5 years or 0–10 years
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were given IPT during the peak malaria transmission season [4–
6]. The IPTc strategy is cost-effective [7] and a high level of
coverage can be obtained when IPTc is delivered by community
health workers [8].
The sample size of these initial studies was relatively small, with
fewer than 500 subjects per treatment arm, and they were
conducted in areas where the utilisation of insecticide treated
bednets (ITNs) was low. Therefore, two larger studies of IPTc
(about 1500 subjects per arm) were conducted in Mali and
Burkina Faso in 2008 [9,10] to determine the degree to which
IPTc given during the malaria transmission season could reduce
the incidence of clinical malaria in children who slept under an
ITN. In the study conducted in Mali, children aged 3–59 months
of age were randomized to receive IPT with sulphadoxine-
pyrimethamine (SP) plus amodiaquine (AQ) or placebos on three
occasions at monthly intervals during the 2008 malaria transmis-
sion season, starting in August 2008. All children received a long
lasting insecticide treated net (LLIN) at the beginning of the
malaria transmission season and were followed through the 2008
malaria transmission season (intervention period) to assess the
safety and effects of the intervention. Results of the safety and
efficacy of IPTc on the incidence of clinical malaria, severe
malaria, malaria infection, anemia and anthropometric indicators
during the 2008 malaria transmission season have been reported
previously [9]. In brief, administration of IPTc resulted in an 82%
reduction in the incidence of uncomplicated malaria and an 87%
reduction in the incidence of severe malaria. The medication was
well tolerated and there were no serious drug related adverse
events.
A concern over the use of IPTc is that it may impair the
acquisition of naturally acquired immunity leading to an increase
in the incidence of malaria in the period after treatment is stopped,
as was seen when chemoprophylaxis was given to African infants
or children [11,12]. No significant rebound in the incidence of
clinical malaria in the year after IPTc was given was observed in
the initial studies conducted in Senegal, Mali and Ghana [4–6].
However, a higher prevalence of anaemia at the end of the year
following IPT administration was seen in the Senegalese study
(10% in the IPT arm versus 6% in the placebo arm; p= 0,02)
although there was no significant difference in mean haemoglobin
concentrations between the two arms [13]. In Senegal, children
who had received IPTc had lower malaria antibody titres than
children who had received placebos [14]. For these reasons, we
followed children recruited to the large IPTc trial in Mali to
determine whether they were at increased risk of malaria in the
year after IPTc was given.
Methods
The protocol of the trial and its amendment (Protocol S1), and
CONSORT checklist (Checklist S1) are available as supporting
information.
Details of the study sites, the overall design of the trial and the
surveillance procedures used have been published previously [9]
and are, therefore, summarized only briefly in this paper. Similar
surveillance procedures were used in the post-intervention follow-
up period to those employed during the intervention period.
Study sites
The study was conducted in two villages, Djoliba and Siby, and
in the small town of Ouelessebougou in the district of Kati in the
savannah region of Mali. Djoliba and Siby are located 40 and
30 km south west of the capital city Bamako respectively and
Ouelessebougou is located 80 km south of Bamako. Each locality
has a community health centre. A research team composed of
physicians and medical residents was established in each of the
three community health centres to follow up and provide health
care to the study participants.
Study design and participants
The study was an individually randomised, placebo controlled
trial. A total of 3017 children aged 3–59 months were randomized
in a 1: 1 ratio to receive IPT with sulphadoxine-pyrimethamine
(SP) plus amodiaquine (AQ) (n = 1509) or their placebos (n = 1508)
on three occasions at monthly intervals during the peak period of
malaria transmission starting in August 2008. A long lasting
insecticide treated net (LLIN) (PermaNetH; www.vestergaard-
frandsen.com) was provided at enrollment to all the participants.
Parents or guardians were instructed on how to use the net and the
importance of using the net regularly was emphasized. Participants
were followed to the end of the 2008 malaria transmission season
(intervention period) to assess the safety and efficacy of the
intervention and to the end of the 2009 transmission season to look
for any rebound effect from the intervention given during the
previous year.
Endpoints
The primary endpoint for the follow-up study was the incidence
of clinical malaria during the follow-up malaria transmission
season (July to November 2009). Clinical malaria was defined as
the presence of fever (axillary temperature $37.5uC) or a history
of fever in the past 24 hours and the presence of Plasmodium
falciparum asexual parasitaemia at a density greater or equal to
5,000 parasites per ml. Secondary endpoints were (i) the incidence
of clinical malaria during the whole post-intervention period
(December 2008 to November 2009), (ii) the incidence of severe
malaria defined according to the WHO criteria [15], (iii) the
prevalence of malaria infection defined as the presence of asexual
P. falciparum parasitaemia during the high transmission season and
at the end of the malaria transmission season, (iv) the prevalence of
mild, moderate or severe anaemia defined as a haemoglobin (Hb)
concentration,11 g/dL, ,8 g/dL and ,5 g/dL respectively at
the end of the malaria transmission season and (v) the incidence of
hospital admission defined as a stay of at least 24 hours in hospital
for treatment during the follow-up period.
Follow –up
Passive surveillance for clinical malaria continued after the end of
the intervention period (6–7 weeks after the final round of IPTc had
been given) to the end of the subsequent transmission season. Parents
were encouraged to bring their child to a study health centre, where
medical staff were available 24 hours a day and 7 days a week, if
their child became unwell. A finger prick blood sample was obtained
from any study child with fever (an axillary temperature of 37.5uC or
higher) or a history of fever within the previous 24 hours for
preparation of a blood film, measurement of Hb concentration and
for a rapid diagnostic test (RDT) for malaria OPTIMAL ITH
(Diamed AG, Cressier FR, Switzerland). Children who had a
positive RDT for malaria were treated immediately with arte-
mether/lumefantrine (AL). Severe cases were admitted to the health
centre or referred to the paediatric ward of the Gabriel Toure´
Hospital in Bamako. Causes of death were assessed within a month
of death using a modified version of the INDEPTH post-mortem
questionnaire (http://www.indepth-network.org/index.php?option=
com_ content&task =view&id= 96&Itemid=184).
Visits were made to the home of a randomly selected sample of
150 children each week during the post-intervention rainy season
(July to November, 2009). During these home visits, the use of a
Malaria Morbidity the Year following IPTc in Mali
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LLIN was assessed by asking if the child had slept under an LLIN
the previous night and the presence of the net was checked by field
staff. In addition, the axillary temperature of each child was taken
and a blood film obtained regardless of whether or not the child
had fever to measure the prevalence of malaria infection.
At the end of the 2009 malaria transmission season, a cross-
sectional survey of all the children enrolled into the study was
carried out. A clinical examination was performed, thick and thin
blood films were prepared and haemoglobin concentration was
measured.
Laboratory methods
Thick blood films were air dried, stained with Giemsa and
examined for malaria parasites by two well-trained technicians.
One hundred high power fields were examined before a film was
declared negative. Parasite density was determined by counting
the number of parasites present per white blood cell (WBC) on a
thick smear and assuming a WBC count of 8,000 per ml. In the
case of a discrepancy (positive/negative or a difference in parasite
density greater than 30%), a third reading was done. The median
parasite density of two or three readings was used. Haemoglobin
concentrations were measured using a haemoglobin analyzer
(HemocueH HB 301, Angelholm, Sweden) on blood obtained by
finger prick.
Data management and analysis
Data were collected on standardized forms, double-entered and
verified using MS Access and then exported to Stata (StataCorp,
College Station, Texas, US) for additional cleaning and analysis. A
data analysis plan was written and submitted to the DSMB prior to
analysis. An intention-to-treat analysis was performed. The
intervention period was defined as the period from the first dose
of IPT administration to the end of November 2008 (42 days after
the third dose of IPT). The post-intervention period of high
malaria transmission was defined as the period from July to
November 2009 and the whole post intervention period was
defined as the period from December 2008 to November 2009,
which included the low malaria transmission season (dry season
from December 2008 to June 2009).
Incidence rates of clinical malaria, severe malaria and hospital
admissions were calculated by dividing the number of episodes
by the total child days at risk. Children were not considered at
risk for 21 days after treatment for an episode of malaria and
these days were not included in the calculation of the child days
at risk. The incidence rates in the two treatment groups were
compared using Cox regression to estimate the incidence rate
ratio (IRR), with adjustment for age, gender and locality, and
using a robust standard error to allow for the lack of
independence among repeated episodes in the same child. Time
to first episode of clinical malaria in the two arms was examined
using Kaplan-Meier plots and compared using the log rank test.
The prevalence of malaria infection was compared between the
previous intervention and control groups using a generalized
linear model, and prevalence ratios (PRs) were adjusted for age,
sex and village.
Anthropometric data collected at the end of the 2009 malaria
transmission season were analysed as previously described [9]. Z-
scores for weight-for-age (WAZ; underweight), height-for-age
(HAZ; stunting) and weight-for- height (WHZ; wasting) were
determined. The WHO child growth standard (http://www.who.
int/childgrowth/software/en/) was used to define wasting,
stunting and being underweight and to code these variables as
binary using z-scores with a score of,22 as a cut-off [16]. A
generalized linear model was fitted with age, sex and village as
covariates to estimate relative risks (RRs) of anthropometric
indicators for the comparison between children who had
previously received IPTc and those who had received placebos
during the previous year.
Ethics
The study protocol was reviewed and approved by the Ethical
Committee of the Faculty of Medicine, Pharmacy and Dentistry,
University of Bamako, Mali and by the Ethics Committee of the
London School of Hygiene and Tropical Medicine. Individual,
written, informed consent was obtained from a parent or guardian
of each child prior to screening and enrolment. A Data and Safety
Monitoring Board (DSMB) was established and monitored the
trial with the support of a local medical safety monitor. GCP
monitoring of the trial was performed by PharmaClin (http://
www.pharmaclin.com).
Results
Characteristics of children at the start of the follow-up
high malaria transmission period
In 2008, 1509 and 1508 children were randomly assigned to
receive IPTc with SP+AQ or placebos of these drugs respectively.
One thousand three hundred and ninety-six of the 1509 children
(92.5%) initially randomised to receive IPTc were available for
follow-up on July 1st 2009. Five children had died, the families of
16 withdrew consent, 4 children were allergic to SP or AQ and
were therefore excluded, and 96 had migrated out of the study
area (Figure 1). One thousand four hundred and six of the 1508
children (93.2%) assigned to receive placebos were available for
follow-up on July 1st 2009. Four of these children had died, the
families of 15 withdrew consent and 83 had migrated out of the
study area. During the high malaria transmission season, a further
41 subjects in the intervention arm were lost to follow-up (5 died,
32 migrated and 4 withdraw consent) and 34 were lost to the
control arm (3 had died and 31 migrated). The proportion of
children who completed the whole study was 89.8% (1355/1509)
in the intervention arm and 90.9% (1372/1508) in the control arm
(P= 0.29). The age and sex distributions of the children available
for follow-up were similar in the two arms (Table 1). The mean
age of the former intervention group was 40.6 months (95%CI
39.7–41.5) and that of the former control group 40.9 months
(95%CI 40.0–41.7). The distribution of children between
treatment arms was similar in the three study localities. The
proportion of children seen during weekly visits who were reported
to have slept under a LLIN during the previous night did not differ
between children who had previously received IPTc (97.3%) or
placebo (96.8%).
Incidence of clinical malaria during the post intervention
period
The incidence of clinical malaria in the two study groups during
the high malaria transmission period of the post intervention year
is presented in Table 2. From July to November 2009, the high
transmission period, 969 episodes of clinical malaria were
recorded in the former intervention arm versus 913 in the former
control group. The incidence of malaria in children from the
former treatment arm was 1.87 (95%CI; 1.76–1.99) episodes per
child year over the follow-up period compared with an incidence
of malaria of 1.73 (95%CI 1.62 – 1.85) episodes per child year in
those who had previously received placebos (IRR=1.09; 95%CI
0.99–1.21) (P = 0.08). In children aged 24 months or more at
enrolment there was a slightly greater tendency towards an
increase in the incidence of malaria in children who had received
Malaria Morbidity the Year following IPTc in Mali
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IPTc (IRR=1.12; 95%CI 0.99–1.26) (P = 0.06), but there was no
evidence that the effect of IPTc on clinical malaria in the
subsequent malaria transmission period was modified by age
(P = 0.53). Analyses that considered the whole post intervention
period (December 2008 to November 2009) (Table 3) showed a
similar IRR when children who had received IPTc in 2008 were
compared to children who had received placebos (IRR=1.09;
95%CI 0.99–1.20) (P = 0.07).
Kaplan-Meier survival estimates of the proportion of children
who remained free of malaria during the high malaria transmission
Figure 1. Study flow chart.
doi:10.1371/journal.pone.0023390.g001
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period of the post intervention year were similar in both groups
(Figure 2).
There was not strong evidence of an increase in the incidence of
malaria post-intervention (data not shown) when a malaria episode
was defined as fever or history of fever and positive asexual
parasitaemia of any density (IRR=1.07; 95%CI 0.98–1.18)
(P = 0.13).
Incidence of severe malaria during the post intervention
period
The incidence of severe malaria in children in the two study
groups during the post- intervention period is presented in Table 4.
During the high transmission period of the post- intervention year,
16 cases of severe malaria occurred, 8 in the former intervention
group (incidence rate = 0.0140 per child year at risk) and 8 in the
former control arm (incidence rate = 0.0139 per child year) giving
an IRR of 0.99 (95% CI 0.38–2.68) (P = 0.99). There were few
additional cases in the intervening dry season, two in the group
that had previously received IPTc and one in the group who had
previously received placebos.
Incidence of hospital admissions and deaths post
intervention and during the whole study period
During the high malaria transmission season of the post
intervention period, eight hospital admissions were recorded in
children who had previously received IPTc compared to seven in
children who had received placebos. The incidence rates of
hospital admission did not differ between the two groups of
children (IRR=1.16; 95%CI 0.42–3.23) (P = 0.77). This observa-
tion was not altered when the low malaria transmission (dry)
season post intervention was included (IRR=1.55; 95%CI 0.78–
3.11) (P = 0.21) (Table 5).
During the high malaria transmission season of the post
intervention year, five deaths were recorded amongst children
who had previously received IPTc compared with four deaths
among those who had previously received placebos.
Malaria infection during the post intervention high
transmission season
From July to November 2009, home visits were made to 1352
children who had previously received IPTc and to 1348 children
who had previously received placebos to measure the prevalence
of malaria infection; 172 and 168 children in the two groups were
not found and microscopy results were available for 1179 and
1180 children respectively. The number of children who carried a
malaria infection was 87 (7.4%) in children from the former
intervention arm and 89 (7.5%) in children from the former
control arm (PR=0.99; 95%CI0.73–1.33) (P = 0.95). The geo-
metric mean parasite densities in positive films were also similar in
the former intervention (3360/mL; 95%CI 2017/mL–55401/mL)
and control groups (3394/mL; 95%CI 1958/mL–5883/mL)
(P= 0.96), the ratio between the two treatment arms was 1.01
(95%CI 0.48–2.12).
Malaria infection, anaemia and anthropometric indicators
at the end of the high malaria transmission season in the
post intervention year
At the end of post intervention malaria transmission season,
1355 children from the former intervention group and 1372
children from the former control group were studied (Table 6).
Microscopy slides for 7 and 16 children from these respective
groups were lost or broken. Two hundred and twenty of the 1348
children (16.3%) in the former treatment arm were parasitaemic
compared to 191 of the 1356 children (14.1%) in the former
control group (PR=1.17; 95%CI 0.96–1.14) (P = 0.12). Amongst
children who had a malaria infection, the geometric means of
parasite density were similar in the two treatment arms with a
Table 1. Distribution of children by age, sex and village at the
beginning of the high malaria transmission season in the post
intervention year.
Intervention Control
N=1396
% (n)
N=1406
% (n)
Age (months)
12–23 21.5 (300) 20.2 (284)
24–35 21.6 (302) 21.7 (305)
36–47 19.9 (277) 20.4 (287)
.= 48 37.0 (577) 37.7 (530)
Sex
Male 50.2 (706) 47.4 (662)
Female 49.8 (700) 52.6 (734)
Locality
Djoliba 50.2 (281) 49.8 (279)
Ouelessebougou 50.1 (742) 49.9 (739)
Siby 50.7 (386) 49.3 (375)
doi:10.1371/journal.pone.0023390.t001
Table 2. Incidence of malaria by age group during the post intervention, high malaria transmission season (July – November
2009).
Former Intervention Former Control
Age {
(months)
Episodes
(child years)
Incidence rate$
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted
IRR (95% CI) P-value
Adjusted*
IRR (95% CI) P-value
,24 294 (212.0) 1.39 (1.24–1.55) 273 (205.3) 1.33 (1.18–1.50) 1.04 (0.86–1.26) 0.67 1.05 (0.86–1.26) 0.64
24+ 675 (306.2) 2.20 (2.04–2.38) 640 (321.6) 1.98 (1.84–2.15) 1.12 (0.99–1.25) 0.07 1.12 (0.99–1.26) 0.06
Overall 969 (518.1) 1.87 (1.76–1.99) 913 (526.9) 1.73 (1.62–1.85) 1.08 (0.98–1.20) 0.12 1.09 (0.99–1.21) 0.08
{Age at the beginning of the intervention in August 2008.
$Malaria episode was defined as fever or history of fever with 5000 or more asexual forms of P. falciparum per mL and absence of any other obvious cause of fever/illness.
*Adjusted for age sex, village and lack of independence among repeated episodes in the same child.
doi:10.1371/journal.pone.0023390.t002
Malaria Morbidity the Year following IPTc in Mali
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23390
geometric mean of 3943 m/L (95%CI 2863/mL–5431/mL) in the
former intervention arm versus 4429 (95%CI 2979/mL–6002/mL)
in the former control arm (P= 0.76).
During the 2009 end of malaria transmission season cross-
sectional survey, haemoglobin concentrations were measured in
1350 children who had previously received IPTc and in 1360
children who had previously received placebos (Table 6). Mean
Hb concentrations were similar in the two treatment arms
(10.67 g/dL [95%CI: 10.60 g/dL–10.74 g/dL] versus 10.69 g/
dL; [95%CI: 10.62 g/dL–10.76 g/dL]); the difference was only
0.019 g/dL (95%CI–008–0.118) (P = 0.70). The proportion of
children who were anaemic (Hb,11 g/dL) was 56.2% in the
former intervention arm and 55.6% in the former control arm
(adjusted PR=1.01; 95%CI 0.91–1.12) (P = 0.84). The propor-
tions of children with moderately severe anaemia (Hb,8 g/dL)
were similar in the two groups, 2.9% in children who had
previously received IPTc and 2.7% in children who had previously
received placebos (PR=1.05; 95%CI 0.67–1.65) (P = 0.84).
Z scores were calculated for 1051 children from the former
intervention arm and for 1057 children from the former control
arm (Table 6). The proportions of wasted, stunted and
underweight children amongst those who had previously received
IPTc were 4.7% (49), 20.8% (219) and 11.3% (119) respectively. In
children who had previously received placebos, the equivalent
proportions were 4.1% (43), 21.5% (227) and 12.2% (129)
respectively. There was no increased risk of wasting (RR=1.14;
95%CI 0.75–1.74) (P = 0.54), stunting (RR=0.98; 95%CI 0.79–
1.21) (P = 0.85) or being underweight (RR=0.94; 95%CI 0.72–
1.23) (P = 0.66) post-intervention in children who had received
IPTc during the previous high malaria transmission season.
Discussion
This study assessed whether, in a context of a high usage of
ITNs, children who had received intermittent preventive treat-
ment with SP +AQ during one malaria transmission season were
at increased risk of malaria morbidity during the subsequent
malaria transmission season as consequence of lack of exposure to
malaria parasites and consequent impairment of immunity. The
study showed a small increase in clinical episodes of malaria
during the post intervention high malaria transmission season in
children who had previously received IPTc, a rate ratio of 1.09,
Table 3. Incidence of malaria by age group during the whole post-intervention period (December 2008 – November 2009).
Former Intervention Former Control
Age{
(months)
Episodes
(child years)
Incidence rate$
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted
IRR (95% CI) P-value
Adjusted*
IRR (95% CI) P-value
, 24 335 (548.5) 0.61 (0.55–0.68) 315 (529.4) 0.59 (0.53–0.66) 1.02 (0.85–1.23) 0.80 1.03 (0.86–1.23) 0.77
24+ 776 (803.2) 0.97 (0.90–1.04) 730 (833.8) 0.87 (0.81–0.94) 1.12 (0.99–1.25) 0.05 1.13 (1.00–1.27) 0.04
Overall 1111 (1352) 0.82 (0.77–.87) 1045 (1363) 0.77 (0.72–0.81) 1.08 (0.98–1.19) 0.12 1.09 (0.99–1.20) 0.07
{Age at the beginning of the intervention in August 2008.
$Malaria episode was defined as fever or history of fever with 5000 or more asexual forms of P. falciparum per mL and absence of any other obvious cause of fever/illness.
*Adjusted for age sex and village.
doi:10.1371/journal.pone.0023390.t003
Figure 2. Survival estimates of the proportion of children who remained free of malaria, defined as fever or history of fever and a
P. falciparum parasite density of at least 5000/ml, during the high malaria transmission season post intervention (July 2009 -
November 2009).
doi:10.1371/journal.pone.0023390.g002
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with a confidence interval from 0.99 to 1.2. This is consistent with
the results obtained in previous smaller studies undertaken in Mali,
Senegal and Ghana that found no evidence of an important
increase in malaria morbidity after administration of IPT in
children for a single transmission season [4–6]. In the previous
study in Senegal, there was a slightly increased risk of malaria
among older children [4], which is also consistent with our
findings, although in our study there was no evidence that the
relative increase in risk varied with age (P= 0.53).
ITN usage in children enrolled in these three previous studies
was low (,5%) while in our study more than 96% of the children
used an ITN. A meta-analysis of the three previous studies found a
similar increase (11%, 95% CI21% to 24%) in malaria morbidity
[13] suggesting that the use of ITN did not affect substantially the
relative risk of malaria after the cessation of IPT in children. A
surprising feature of this study was the high incidence of malaria in
children who slept under an ITN during both the intervention and
the follow-up years indicating that the use of an ITN alone is not
sufficient to achieve a high degree of protection against malaria in
this area of Mali. The efficacy of the nets and the absence of a high
degree of resistance to pyrethroids in the study area was confirmed
in 2009 [9].
In a parallel study conducted in Burkina Faso, with a similar
design and a similar large sample size, a 12% increase in malaria
morbidity was seen in the post intervention period, [Unpublished].
The confidence interval was narrower in that study, reflecting the
larger number of malaria episodes.
In line with previous studies [13], as well as with the parallel
study in Burkina Faso [Unpublished], there was no increase in
severe morbidity (severe malaria, hospital admission or death)
during the follow-up period. However, despite its relatively large
size, our study had limited power to detect differences in these
end-points. Nevertheless, the fact that no study has so far suggested
an increase in severe disease is reassuring.
No evidence was found for an increase in malaria parasite
prevalence or parasite density in subjects who had previously
received IPTc during the post-intervention period in line with the
results of previous studies [4,6,13]. In the parallel study in Burkina
Faso, the proportion of children with malaria parasite at weekly
visits during the post-intervention period was lower in subjects who
had received IPT in the previous malaria transmission season but
similar between the two groups at the end of the subsequent
transmission season. However, mean parasite density was higher
during the subsequent transmission season in children who had
previously received IPTc in the Burkina Faso study [Unpublished].
At the end of the post intervention malaria transmission season,
the prevalence of anemia, moderate anemia and nutritional
indicators (wasting, stunting and being underweight) were similar
among the subjects who had previously received IPTc and those
who had not. Similar results were found in the parallel study in
Burkina Faso [Unpublished]. However, Kweku et al [6] found a
small increase in anemia in the intervention group in the year
following the intervention period.
In summary, the results of this study are internally consistent, and
consistent with those of other similar studies in different settings with
different levels of malaria transmission, in showing that adminis-
tration of an effective IPTc regimen for one malaria transmission
season may result in a small increase in the incidence of clinical
episodes of malaria during the subsequent malaria transmission
season but no increase in the prevalence of malaria parasitaemia,
Table 4. Incidence of severe malaria in the high malaria transmission period of the post intervention year and during the whole
post intervention period.
Former Intervention (SP+AQ) Former Control
Periods
Episodes
(child years)
Incidence rate
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted
IRR (95% CI) P-value
Adjusted*
IRR (95% CI) P-value
Post intervention
high malaria
transmission season
(Jul 09 – Nov 09)
8 (570.7) 0.0140
(0.0070–0.0280)
8 (575.9) 0.0139
(0.0069–0.0278)
1.00
(0.38–2.68)
0.99 1.00
(0.38–2.68)
0.99
Whole post-
intervention period
(Dec 08 – Nov 09)
10 (1414.0) 0.0070
(0.0038–0.0131)
9 (1411.0) 0.0064
(0.0033–0.0122)
1.11
(0.45–2.72)
0.81 1.11
(0.45–2.74)
0.82
*Adjusted for age, sex and village.
doi:10.1371/journal.pone.0023390.t004
Table 5. Incidence of all-cause hospital admissions in the high malaria transmission period of the post intervention year and
during the whole post intervention period.
Former Intervention (SP+AQ) Former Control
Periods
Episodes
(child years)
Incidence rate
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted
IRR (95% CI) P-value
Adjusted*
IRR (95% CI) P-value
Post intervention high
malaria transmission
season (Jul 09 – Nov 09)
8 (570.7) 0.014
(0.007–0.028)
7 (576.0) 0.012
(0.006–0.025)
1.15
(0.41–3.18)
0.78 1.16
(0.42–3.23)
0.77
Whole post-intervention
period (Dec 08 – Nov 09)
20 (1415) 0.014
(0.009–0.022)
13 (1424) 0.009
(0.005–0.016)
1.54
(0.77–3.11)
0.22 1.55
(0.78–3.11)
0.21
*Adjusted for age, sex and village.
doi:10.1371/journal.pone.0023390.t005
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anaemia or malnutrition. It is possible that the risk of rebound
malaria may be influenced by the level of transmission but currently
there are too few data to determine this. No increase in severe
malaria has been seen in this or any other study but the numbers of
subjects studied so far have been too small to exclude a small effect.
The possibility of a small rebound effect must be set against the
major benefit seen during the period in which the intervention was
given, with an 80% reduction in the incidence of severe malaria and
a probable, substantial reduction in all cause mortality [13].
A limitation of this and previous studies that have assessed the
post-intervention consequences of IPTc is that the interventions
have been given during a single malaria transmission season whilst,
if IPTc is to be deployed as a malaria control tool, it is envisaged that
children would receive seasonal IPTc for several years and it is
possible that this would have a bigger impact on the acquisition of
naturally acquired immunity than seen in this study. In a previous
study of seasonal chemoprophylaxis undertaken in an area of the
Gambia with a pattern of malaria similar to that ofMali, the risk of a
rebound in clinical malaria increased with each year that a child had
received seasonal prophylaxis only becoming substantial when a
child had received prophylaxis for several seasons following birth
[11]. There was no increase in mortality in the Gambian study.
However, the findings of this Gambian study indicate that if IPTc is
recommended as policy and implemented as part of national
malaria control programmes in African countries with highly
seasonal transmission of malaria, long-term follow-up of the impact
of IPTc on naturally acquired immunity will be essential.
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